BIBERACH (dpa-AFX) - Der Pharmakonzern Boehringer Ingelheim sieht Fortschritte bei den Regelungen zur Nutzung von ...
A persistent, often progressive, lung disease, COPD results from chronic inflammation that leads to structural changes ...
INGELHEIM, Germany & SOUTH SAN FRANCISCO, Calif., October 09, 2024--Boehringer Ingelheim and Circle Pharma (Circle) announce a new research collaboration and license agreement with the shared goal to ...
The building’s development is part of a five-year $7.8bn investment plan by Boehringer Ingelheim. As part of the investment, the company opened a biomass power plant in Ingelheim, Germany ...
Learn more at https://www.boehringer-ingelheim.com. This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business.
Learn more at https://www.boehringer-ingelheim.com. This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business.
The U.S. FDA Breakthrough Therapy designation is for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate or advanced fibrosis, based on surv ...
Learn more at https://www.boehringer-ingelheim.com. This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business.
Learn more at https://www.boehringer-ingelheim.com. Intended Audiences Notice This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback